News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
FDA
Warner Chilcott Gets FDA OK for 150 mg Acne Drug
June 23, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Warner Chilcott Ltd. said Monday the Food and Drug Administration approved a 150 mg strength of Doryx delayed-release tablets as a treatment for severe acne.
Twitter
LinkedIn
Facebook
Email
Print
FDA
Approvals
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Regulatory
It’s Official: FDA Will Now Default to One Clinical Trial for Drug Applications
February 19, 2026
·
3 min read
·
Tristan Manalac
FDA
FDA Reverses Course on Moderna’s mRNA Flu Shot Application, Promising August Decision
February 18, 2026
·
3 min read
·
Heather McKenzie
Podcast
Modernagate Fallout, Disc’s Rejection, Compass’ Psilocybin Data, CDC’s Lost Leaders
February 18, 2026
·
1 min read
·
Heather McKenzie
Rare disease
Disc’s Regulatory Comeback Plan for Rejected Drug Relies on Old FDA Leadership
February 17, 2026
·
3 min read
·
Annalee Armstrong